Company Overview and News

Will High Rates, Volatility Aid E*TRADE (ETFC) Q1 Earnings?

11h zacks
E*TRADE Financial Corporation (ETFC - Free Report) is scheduled to report first-quarter 2018 results on Apr 19. The company is expected to witness year-over-year growth in revenues and earnings.
Upvote Downvote

Why Earnings Season Could Be Great for E*TRADE (ETFC)

2018-04-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Upvote Downvote

Interactive Brokers (IBKR) Beats on Q1 Earnings, Costs Rise

2018-04-18 zacks
Interactive Brokers Group, Inc. (IBKR - Free Report) released first-quarter 2018 results. Earnings per share of 63 cents surpassed the Zacks Consensus Estimate of 56 cents. Also, the figure was higher than prior-year quarter’s figure of 34 cents per share. Results benefited from an improvement in revenues and rise in DARTs. Further, the Electronic Brokerage segment continued to perform decently. However, higher expenses were the undermining factor.
Upvote Downvote

Schwab’s Q1 Numbers Validate Pre-Earnings Bullishness on TD Ameritrade Holdings Corp. Stock

2018-04-17 investorplace
If you’re not sure what to expect this coming Monday when TD Ameritrade Holding Corp. (NASDAQ:AMTD) reports its Q1 earnings, you’re not alone. Current and would-be owners of AMTD stock have received mixed messages, including from the online broker itself.
Upvote Downvote

Schwab (SCHW) Beats Q1 Earnings as Trading Activity Improves

2018-04-16 zacks
Charles Schwab’s (SCHW - Free Report) first-quarter 2018 earnings of 55 cents per share surpassed the Zacks Consensus Estimate by a penny. Also, earnings surged 41% from the prior-year quarter. Schwab’s shares were up more than 2% in early market trading. Rise in trading revenues was perhaps the primary reason that cheered investors. Notably, price reaction during the full trading session will provide a better idea about how investors accepted the results.
Upvote Downvote

E*TRADE's (ETFC) Ratings Upgraded by Moody's, Outlook Stable

2018-04-09 zacks
E*TRADE Financial (ETFC - Free Report) and E*TRADE Bank’s ratings have been upgraded by Moody's Investors Service, the rating arm of Moody's Corporation (MCO - Free Report) , concluding the review for upgrade, initiated in January 2018. However, the rating firm’s outlook for the bank has been affirmed at “stable”. The investment bank’s senior unsecured rating has been upgraded to Baa2. E*TRADE Bank’s long-term ratings has been upgraded to A2 and short-term deposit rating upped to Prime-1.
Upvote Downvote

4 Reasons to Invest in Interactive Brokers (IBKR) Stock Now

2018-04-04 zacks
The investment management industry seems to be well positioned for growth, given the stabilizing economy and improving rate environment. Hence, it is a wise idea to add a stock from the industry to your portfolio now. Of the many options available, Interactive Brokers Group, Inc. (IBKR - Free Report) seems to be an attractive pick right now, given its strong fundamentals and solid growth prospects.
Upvote Downvote

Interactive Brokers Stock Falls 3.6% as March DARTs Decline

2018-04-03 zacks
Shares of Interactive Brokers Group, Inc.’s (IBKR - Free Report) have declined 3.6% following the release of its Electronic Brokerage segment’s performance metrics for March 2018. The segment, which deals with clearance and settlement of trades for individual and institutional clients globally, reported a fall in Daily Average Revenue Trades (DARTs) for the reported month. Total client DARTs came in at 903,000, decreasing 11% from February 2018 but increasing 39% from March 2017.
Upvote Downvote

TD Ameritrade (AMTD) Rallies 11.9% QTD: Is More Upside Left?

2018-03-29 zacks
During the last earnings season, performance of the financial stocks was decent. One such investment bank — TD Ameritrade Holding Corporation (AMTD - Free Report) — has rallied 11.9% quarter to date, significantly outperforming the industry’s slight gain of 1.1%. This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business.
Upvote Downvote

E*TRADE (ETFC) Moves Up 12.1% YTD: Is More Upside Left?

2018-03-27 zacks
During the last earnings season, performance of the financial stocks was decent. One such investment bank — E*TRADE Financial Corporation (ETFC - Free Report) — has rallied 12.1% year to date, significantly outperforming the industry’s slight decline. This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business.
Upvote Downvote

ETFC / E*TRADE Financial, Inc. DEF 14A

Upvote Downvote

ETFC / E*TRADE Financial, Inc. DEFA14A

Upvote Downvote

FFTY: An Elegant Solution

2018-03-26 seekingalpha
Launched in April 2015, the Innovator IBD 50 ETF (FFTY) seeks to track the IBD 50 Index, giving investors such as myself the ability to benefit from the methodology of the CAN-SLIM strategy without the need for making the individual trades and avoiding the costs (fees, tax implications) associated with doing so. The below chart shows the performance of FFTY vs. the S&P 500 (SPY) since launch:
Upvote Downvote

LPL Financial Stock Falls Despite Improved February Metrics

2018-03-26 zacks
Despite an improvement in monthly activity for February 2018 from the prior month, shares of LPL Financial Holdings Inc. (LPLA - Free Report) have declined 4.3% following the release. The figures in the reported month include assets from its acquisition of the broker/dealer network of National Planning Holdings, Inc. Notably, the company projects further total asset transfer from National Planning Holdings to be in the range of $70-$75 billion, driven by more direct business assets joining its platform.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 269246401